The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,761.00
Bid: 1,757.50
Ask: 1,758.00
Change: 27.50 (1.59%)
Spread: 0.50 (0.028%)
Open: 1,736.00
High: 1,767.00
Low: 1,736.00
Prev. Close: 1,733.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

London open: Stocks gain ahead of central bank announcements

Thu, 04th Oct 2012 08:23

- Investors await BoE and ECB decisions, FOMC minutes- Tate & Lyle jumps after Credit Suisse upgrades- Halfords appoints new CEO after strong Q2European stock markets have opened with moderate gains ahead of what is likely to be a busy day on the economic front, with rate decisions due out from the Bank of England (BoE) and European Central Bank (ECB) later today, as well as the minutes of the latest Federal Reserve meeting.The BoE's Monetary Policy Committee (MPC) is set to reveal whether it has made any alterations to its key interest rate and asset purchase programme (also known as quantitative easing, or QE) at noon.The smart money is on there being no change, with the interest rate staying at 0.5% and the asset purchase (quantitative easing, or QE) pot staying at £375bn. However, some are expecting an increase in QE and a 25 basis point rate cut in November.The ECB is also expected to remain in 'wait-and-see' mode when it reveals its policy decision after midday. Analysts believe that the ECB will wait for Spain to make the next move considering that it already announced its bond purchase plan for ailing countries that request aid. The key interest rate currently stands at 0.75% after it was cut by 25 basis points early in the year. The deposit rate is at 0%. Analyst Craig Erlam from Alpari said: "There's been a lack of volatility in the markets in recent weeks as investors look beyond central banks to the governments for reassurance on the next step in the debt crisis. The uncertainty surrounding Spain has left investors unsure on how to position themselves as we approach near end. Given a lack of details out of the eurozone, there is a hope that the ECB will give us some valuable insight into this."Meanwhile, the Federal Open Market Committee (FOMC) minutes are also on the agenda for later. Analyst Moyeen Islam from Barclays Research said this morning that the minutes should provide more "granularity regarding what the Fed may judge to be a 'sustainable improvement' in the labour market that would underpin any decision to end the current open-ended commitment to asset purchases.FTSE 100: Tate & Lyle gains after broker upgradeSweeteners and food products group Tate & Lyle was the high riser in early trading after Credit Suisse raised its recommendation for the stock from 'neutral' to 'outperform'. The broker said: "There is no easy way to value Tate & Lyle, but it does seem to us to be a better business for all the changes we have seen and that this is not reflected in the share price (which is down 8% year to date versus a staples sector up 18%)."Evraz fell after acquiring an indirect controlling interest in OJSC Raspadskaya, one of Russia's largest producers of coking coal and a supplier to the Russian steel firm.Pharmaceuticals behemoth GlaxoSmithKline gained after saying its joint venture company, Shionogi-ViiV Healthcare, has completed an initial clinical registration package for dolutegravir, its treatment for HIV patients.Supermarket peers Tesco and Sainsbury were among the stocks in the red following their results and trading update yesterday, respectively. Exane BNP Paribas reduced its target price for Tesco this morning from 325p to 300p and reiterated its 'underperform' rating on the shares. FTSE 250: Halfords surges after impressive Q2, new CEO appointmentCar and bike parts retailer Halfords jumped after appointing a new Chief Executive Officer following the abrupt departure of David Wild in the summer, as it revealed that full-year profits would be at the top end of guidance after a strong second quarter.The company expects pre-tax profit to be in the region of £40-42m in the first half on the back of its second quarter performance and an acceleration of operating cost investment. The consensus estimate currently stands at just £35.8m. Fashion chain Ted Baker was in demand after saying that the reaction to its autumn/winter collections has been positive as it unveiled a solid first-half trading performance. FTSE 100 - RisersTate & Lyle (TATE) 691.50p +2.52%Standard Chartered (STAN) 1,421.00p +1.21%Prudential (PRU) 833.00p +1.09%Carnival (CCL) 2,336.00p +0.99%InterContinental Hotels Group (IHG) 1,655.00p +0.98%Barclays (BARC) 222.30p +0.93%International Consolidated Airlines Group SA (CDI) (IAG) 165.20p +0.92%Royal Bank of Scotland Group (RBS) 260.40p +0.89%Diageo (DGE) 1,795.00p +0.84%ITV (ITV) 91.95p +0.82%FTSE 100 - FallersEvraz (EVR) 239.60p -3.11%BHP Billiton (BLT) 1,929.00p -0.72%Tesco (TSCO) 325.75p -0.67%G4S (GFS) 266.50p -0.56%BG Group (BG.) 1,302.00p -0.53%BP (BP.) 436.85p -0.50%CRH (CRH) 1,183.00p -0.50%Johnson Matthey (JMAT) 2,406.00p -0.46%Amec (AMEC) 1,145.00p -0.43%British Land Co (BLND) 521.00p -0.29%FTSE 250 - RisersHalfords Group (HFD) 302.00p +13.53%Ted Baker (TED) 945.00p +3.45%Victrex (VCT) 1,372.00p +3.08%Stobart Group Ltd. (STOB) 115.40p +2.58%Ocado Group (OCDO) 67.70p +2.27%Rentokil Initial (RTO) 84.85p +2.23%Computacenter (CCC) 385.00p +2.18%Paragon Group Of Companies (PAG) 212.30p +2.07%Lonmin (LMI) 548.00p +2.05%FirstGroup (FGP) 197.30p +2.02%FTSE 250 - FallersRank Group (RNK) 146.90p -2.39%Hansteen Holdings (HSTN) 76.30p -2.18%Carpetright (CPR) 630.00p -2.10%IP Group (IPO) 118.60p -1.58%JD Sports Fashion (JD.) 709.00p -1.53%Dechra Pharmaceuticals (DPH) 583.00p -1.10%Bovis Homes Group (BVS) 495.20p -1.06%Kenmare Resources (KMR) 39.75p -1.00%Petra Diamonds Ltd.(DI) (PDL) 115.20p -0.95%Utilico Emerging Markets Ltd (DI) (UEM) 160.12p -0.86%BC
More News
3 Apr 2024 22:01

Biden, Senator Bernie Sanders push companies to cut cost of asthma inhalers, prescription drugs

WASHINGTON, April 3 (Reuters) - President Joe Biden hosted a White House event with U.S. Senator Bernie Sanders on Wednesday to tout their fight against high prescription drug prices and push companies to cut the cost of inhalers for asthma sufferers.

Read more
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.